February 10, 2026
“Uncle algo and his electronic trading dwarfs” are “smelling” the upside as data deluge appears coming
Investors are coming off a 2nd straight day of dramatic gains to which I say BYE and SELL (some) into strength
News: Moderna (MRNA +$0.25 or +0.60% to $41.95 pre-open) signed a Memorandum of Understanding (MoU) for a long-term strategic agreement with the Mexican Government, Laboratorios de Biológicos y Reactivos de Mexico (BIRMEX), and Laboratorios Liomont (Liomont), to enhance Mexico's health sovereignty and mRNA manufacturing resilience. The 5-year agreement will include the supply of MRNA's respiratory vaccine portfolio, as well as technology transfer to Liomont, a Mexican pharmaceutical company with state-of-the-art manufacturing facilities, to produce mRNA-1273, MRNA's COVID-19 vaccine, and establish a reliable in-country supply of respiratory vaccines.
Pre-open Signals: Let the portfolio shake-out, if you understand probabilities, the inevitable is easier to maneuver
Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.
Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t!
February 4, 2026
SGMO continues to fall -$0.0168 or -4.31% to $0.37
Proceeds are estimated at $25 M
SGMO closed <Monday> at $0.5679 and is trading at -$0.1413 or -24.74% to $0.44
Cantor and Wells Fargo Securities are acting as joint book-running managers for the offering.
The offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock.
February 10, 2026
Indexes shaved its “spoils”; present and coming econs and earnings contaminated sector advances
Indexes are coming off a 2nd straight day of gains as tech stocks rallied, building on their Friday comeback. The Dow in particular notched fresh highs on an intraday and closing basis. Investors are hopeful the market can sustain its upward advance after last week’s sell-off failed to meaningfully hurt the market on a technical basis. <CNBC>
Always be ready for an alternate view!
RMi collects, curates, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision
Never leave a retail investor uninformed! It’s not always time to buy or sell; but it is time to KNOW why!
February 4, 2026
SGMO continues to fall -$0.0168 or -4.31% to $0.37 Proceeds are estimated at $25 M SGMO closed <Monday> at $0.5679 and is trading at -$0.1413 or -24.74% to $0.44 Cantor and Wells Fargo Securities are acting as joint book-running managers for the offering. The offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock.
January 25, 2026
AXGN closed +$0.83 or +2.59% to $32.83 with an aftermarket value of +$0.16 or +0.49% Having increased the deal from US$85 million to US$124 M, with the funds earmarked for debt repayment, working capital, and general corporate uses. The gross proceeds expected to be approximately $124 M (assuming no exercise of the underwriters’ option expecting to close on 1/23/26, subject to the satisfaction of customary closing conditions.
January 21, 2026
Another Opinion: Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? https://finance.yahoo.com/news/fda-no-trial-stance-deramiocel-111135647.html I am NOT the only DISSENTER! s Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump. https://finance.yahoo.com/news/capricor-therapeutics-capr-still-attractive-052444220.html FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review process. CAPR expects to submit updates to the BLA in February 2026 to support continued FDA review. As previously disclosed, CAPR provided topline results from its P3 HOPE-3 clinical study to the FDA in late 2025. Rejected for more data. For all my … <some say> … RANTINGS, I say TRUTH … timing will be everything until the FDA “speaks;” the higher CAPR rose from 12/2’s $6.36, the steeper the fall! STICKING to my CONVICTION that Capricor Therapeutics (CAPR) is overbought and whose valuation is disconnected from fundamentals.
3 hours 47 min ago
RMi Closing Bell: Perception becomes reality
12 hours 23 min ago
RMi Pre-opening: After new record highs
12 hours 50 min ago
RMi Pre-opening: After new record highs
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
